Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03726879
Title A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)
Acronym IMpassion050
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | ESP | DEU | CZE | CAN | BRA


No variant requirements are available.